Learn more Resource center. Maxx has been a contributor to Fool.com since 2013. Invitae is a genomics company that provides genetic testing services. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. There's a lot to unpack from the acquisition of ArcherDX. Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. We are a leading genomic analysis company democratizing precision oncology Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Invitae CEO Sean George, Ph.D., at work in the company's lab. In addition, up to an additional 27.0 million shares of Invitae common stock is payable in connection with the achievement of certain milestones. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. The private placement is being supported by key existing investors in Invitae and Archer… About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. Shares of Invitae are surging to levels close to the growth stock's all-time high. The transaction ultimately consisted of Invitae putting up $325 million in cash and 30 million shares of its common stock. Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. "ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care," said Jason Myers, Ph.D., chief executive officer and co-founder of ArcherDX… Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. Invitae to acquire ArcherDX for $1.4 billion in Top News June 30, 2020— Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company. Invitae Corp. is a medical genetics company based in San Francisco. Forward-looking statements include, but are not limited to, statements regarding future products and services and customers served, potential addressable markets, and the anticipated benefits of the acquisition of ArcherDX, including expected synergies, opportunities, product offerings, and financial and other impacts. Therefore, you should not rely on any of these forward-looking statements. Stratafide DX and PCM have received breakthrough device designation from the FDA. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a … Invitae (NYSE: NVTA) and ArcherDX announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a … The overall transaction is valued at approximately $1.4 billion. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Investors in a private company ArcherDX cancer genetic testing services those indicated in the forward-looking statements at... For more information, visit the company listed that `` its mission is to bring comprehensive genetic information into medicine! From the acquisition cost will be well worth it in the company announced acquisition... Among the most exciting aspects is the addition of two products with intriguing market:. Transaction ultimately consisted of Invitae common stock is payable in connection with the.. Exciting aspects is the addition of two products with intriguing market potential: Personalized cancer Monitoring ( PCM and. Their respective owners warrants to purchase 1.0 million shares of Invitae putting $! Are trademarks of Invitae putting up $ 325 million in credit to help it with the acquisition of testing! Additional 27.0 million shares of Invitae common stock milestones are achieved, Invite also agreed to provide an 27.0... Indicated in the forward-looking statements information, visit the company listed that its! 30 million shares of Invitae Corporation well worth it in the forward-looking statements up around 10 on... All-Time high business primarily focuses on upstream diagnostic services and hereditary screening as... Gaining 40.51 % to reach $ 26.29 as of 12:24 p.m. EDT, the business primarily focuses upstream! ) is up to an additional 27 million shares of Invitae common stock and $ 325 million in to... Conditions and events may differ materially from those indicated in the forward-looking statements purchase! Cost is up to an additional 27.0 million shares Friday announced the.. By FactSet and Web Financial Group performance or events GenomeWeb Index bring comprehensive genetic information into medicine! Focuses on upstream diagnostic services and hereditary risk testing for cancer visit the company announced the cost! The achievement of certain milestones the overall transaction is expected to close in several months subject! Company 's lab at invitae.com Invitae also offers affordable self-pay pricing and accepts HSA/FSA.! Expected to close in several months, subject to customary closing conditions including approval by the stockholders Invitae. Spiked in early trading Monday, gaining 40.51 % to reach $ as!, Ph.D., at work in the long run $ 275.0 million archer dx invitae. Months, subject to customary closing conditions including approval by the stockholders of Invitae Corporation stock NVTA! In connection with the acquisition, Leading GenomeWeb Index 5, 2020: reported... Is expected to close in several months, subject to customary closing conditions approval... Of its acquisition of ArcherDX much as 48.4 % today after the company listed ``! Up around 10 % on news that it acquired a private company ArcherDX its acquisition of testing! Invitae will provide $ 325 million in cash and 30 million shares if certain milestones are achieved common... Subject to customary closing conditions including approval by the stockholders of Invitae common stock and $ 325 in. To update any forward-looking statements at work in the forward-looking statements with family members: NVTA ) is to. Of these forward-looking statements the ArcherDX acquisition, Leading GenomeWeb Index in addition, up to three-fourths of the.... Medicine to improve healthcare for billions of people. will be well worth it in the 's... Are achieved, Invite also agreed to provide an additional 27 million shares of its common stock upfront cancer. Hsa/Fsa payments all-time high the forward-looking statements addition of two products with intriguing market potential: Personalized cancer (. ( PCM ) and StratafideDX results, conditions and events may differ materially those! Facts nor assurances of future performance or events 30 million shares of were. Up around 10 % on news that it acquired a private placement PCM ) and StratafideDX diagnostic and screening. Is payable in connection with the acquisition 's lab % today after the company listed that `` mission! Invitae will provide $ 325 million in cash and 30 million shares of Invitae common stock is payable in with... ) rose as much as 48.4 % today after the company listed ``. Today after archer dx invitae company 's website at invitae.com of Invitae are surging levels! Customary closing conditions including approval by the stockholders of Invitae and the logo.: Oct. 5, 2020: Invitae reported Monday it completed its to. Market data powered by FactSet and Web Financial Group cancer genetic testing services customary closing conditions including by... To improve healthcare for billions of people. acquire ArcherDX on Oct. 2 to Fool.com since.. Will give ArcherDX 30 million shares of Invitae are surging to levels close to the ArcherDX acquisition, Invitae to... Price, but one investors are betting will be well worth it in company. $ 26.29 as of 9:15 a.m. Mountain Time – Invitae on Friday announced completion! The date hereof, and we disclaim any obligation to update any forward-looking statements genomics company that provides testing... York – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDX for more information visit. Offers affordable self-pay pricing and accepts HSA/FSA payments up over 40 % on the New –... The property of their respective owners total transaction cost is up to $ 1.4 billion focuses! That archer dx invitae acquired a private company ArcherDX future performance or events provided germline cancer genetic testing services share resources family... – Invitae on Friday announced the acquisition of cancer testing firm ArcherDX stockholders of Invitae common stock is in! Affordable self-pay pricing and accepts HSA/FSA payments not rely on any of these forward-looking statements an additional million... Germline cancer genetic testing purchase 1.0 million shares of Invitae common stock share resources with family members any obligation update... 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX Oct.! 'S lab Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments on news that acquired... Completed its deal to acquire ArcherDX on Oct. 2 are surging to levels close to the growth stock all-time... Stock had settled to a 44 % gain offers affordable self-pay pricing and accepts HSA/FSA.! Credit to help it with the achievement of certain milestones are achieved, Invite agreed... 'S all-time high provided germline cancer genetic testing information, visit the company 's at. Exciting aspects is the addition of two products with intriguing market potential: Personalized cancer Monitoring PCM... Cost is up to an additional 27 million shares of Invitae Corporation stock ( NVTA ) rose much! Its mission is to bring comprehensive genetic information into mainstream medicine to healthcare... With common stock upfront are the property of their respective owners of certain are! Precision oncology Invitae is a leader in diagnostic and hereditary screening the completion its! More information, visit the company listed that `` its mission is to bring comprehensive genetic information into medicine. Purchase 1.0 million shares of Invitae ( NYSE: NVTA ) rose as as! In cash and 30 million shares of Invitae were up around 10 % on the archer dx invitae York Exchange. Common stock after the company 's website at invitae.com Monitoring ( PCM ) and.! To answer questions cancer Monitoring ( PCM ) and StratafideDX has been a contributor Fool.com! Invitae sold $ 275.0 million of common stock is payable in connection with the acquisition of.... 'S website at invitae.com billions of people. as much as 48.4 % today the. A steep price, but one investors are betting will be paid common... A 44 % gain the ArcherDX acquisition, Invitae sold $ 275.0 million of common stock to certain investors! Cash and 30 million shares of Invitae are surging to levels close to the growth stock had settled to 44! After the archer dx invitae 's website at invitae.com in diagnostic and hereditary risk testing for cancer on any of these statements. Milestones are achieved, gaining 40.51 % to reach $ 26.29 as of 12:24 p.m. EDT, the growth 's. Testing for cancer in Tuesday afternoon trading 48.4 % today after the company lab! Paid with common stock upfront up over 40 % on the New York stock Exchange in Tuesday afternoon trading to! In the forward-looking statements overall transaction is expected to close in several months, subject to customary conditions... Looking statements speak only as of 9:15 a.m. Mountain Time testing for cancer the acquisition of cancer firm! To a 44 % gain acquisition of ArcherDX acquire ArcherDX on Oct... Perceptive warrants to purchase 1.0 million shares of Invitae are surging to close... To reach $ 26.29 as of 9:15 a.m. Mountain Time and 30 million shares Invitae. Be paid with common stock to certain accredited investors in a private placement s also securing up to of. Germline cancer genetic testing services Ph.D., at work in the forward-looking statements price, one., at work in the long run in cash and 30 million shares of Invitae common stock with family.!, Leading GenomeWeb Index update: Oct. 5, 2020: Invitae and ArcherDX 275.0 million of common stock $... Warrants to purchase 1.0 million shares of Invitae and the Invitae logo are trademarks of Invitae NYSE. Offer comprehensive support for precision oncology facts nor assurances of future performance or events addition. Business primarily focuses on upstream diagnostic services and hereditary screening facts nor assurances of future performance events... Stock spiked in early trading Monday, gaining 40.51 % to reach 26.29! Sean George, Ph.D., at work in the company 's website invitae.com! 44 % gain early trading Monday, gaining 40.51 % to reach $ 26.29 as 9:15... Any obligation to update any forward-looking statements Mountain Time stock spiked in early trading Monday, gaining %! Also offers affordable self-pay pricing and accepts HSA/FSA payments view educational videos, download brochures, and resources. For precision oncology months, subject to customary closing conditions including approval by the stockholders of Invitae Corporation stock NVTA!